GlassScriptPhysician profile
Reed C Baskin
NPI 1225020613
$1,276.01
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,258 · 2022: $18.34.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $165.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $159.38 | 2019 | |
| Janssen Biotech, INC. | $147.34 | 2019 | |
| Genentech USA, INC. | $100.45 | 2019 | |
| Merck Sharp & Dohme LLC | $76.91 | 2019 | |
| Pfizer INC. | $75.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $61.54 | 2019 | |
| Abbvie INC. | $56.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.42 | 2019 | |
| Amgen INC. | $49.37 | 2019 | |
| Incyte Corporation | $40.19 | 2019 | |
| Genzyme Corporation | $33.08 | 2019 | |
| Celgene Corporation | $26.30 | 2019 | |
| Lilly USA, LLC | $24.36 | 2019 | |
| Seagen INC. | $22.77 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.20 | 2019 | |
| Biocompatibles, INC. | $19.79 | 2019 | |
| Seqirus USA INC | $18.34 | 2022 | |
| Taiho Oncology, INC. | $17.80 | 2019 | |
| Emd Serono, INC. | $16.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2019 | |
| Eisai INC. | $13.38 | 2019 | |
| Tersera Therapeutics LLC | $12.87 | 2019 | |
| Tactile Systems Technology INC | $12.86 | 2019 | |
| Array Biopharma INC | $12.85 | 2019 | |
| Clovis Oncology, INC. | $8.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Baskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.